Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling.
Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, Li Y, Chen X, Keeton AB, Abadi AH, Moyer MP, Grizzle WE, Chang WC, Clapper ML, Piazza GA.
Li N, et al. Among authors: piazza ga.
Mol Cancer Ther. 2013 Sep;12(9):1848-59. doi: 10.1158/1535-7163.MCT-13-0048. Epub 2013 Jun 26.
Mol Cancer Ther. 2013.
PMID: 23804703
Free PMC article.